Gilead Sciences agreed to acquire Arcellx for $7.8 billion in cash and contingent value rights, taking full control of anito‑cel, a BCMA‑directed CAR‑T therapy for relapsed or refractory multiple myeloma. The deal eliminates existing profit‑sharing with Arcellx and accelerates Gilead’s ability to commercialize anito‑cel, which has submitted a BLA with an FDA PDUFA target date of Dec. 23, 2026. Gilead framed the purchase as part of a push to rebuild its cell‑therapy business after Kite’s mixed performance, while Arcellx’s D‑Domain CAR platform adds next‑generation engineering options. Analysts note the acquisition both clears commercialization hurdles and concentrates upside in Gilead—removing milestone and royalty structures that previously limited near‑term economics.